



ASX Announcement | 29 March 2021
Noxopharm Limited (ASX:NOX)

Presentation for Switzer Small and Micro Cap Virtual Investor Day

Sydney 29 March 2021: Australian clinical-stage drug development company **Noxopharm Limited (ASX:NOX)** provides the corporate presentation for the Switzer Small and Micro Cap Virtual Investor Day to be held Tuesday 30 March 2021.

The presentation will focus on the Company's proprietary drug technology platform that is behind the Company's aim in developing a pipeline of drugs to meet the major unmet needs of cancer and septic shock. The link between these two important community ailments is a disturbance in the immune and inflammatory systems, with the Noxopharm technology platform able to address that imbalance.

The presentation reviews the significant progress made in establishing Veyonda® (NOX66) as a highly sought-after, next generation immuno-oncology drug, to be used to boost the anti-cancer effectiveness of most standard anti-cancer therapies including radiotherapy, chemotherapy and immune checkpoint inhibitors.

Also reviewed is the progress of the potential role in using Veyonda to block progression into septic shock, believed responsible for much long-term disability and death in COVID-19 patients.

Dr Kelly will review the Company's progress in generating the underlying proof-of-concept data towards its goal of raising both the value and international profile of Veyonda.

Dr Kelly's presentation titled, "*Switzer Small & Micro Cap Virtual Investor Day Presentation March 2021*" is attached.

Registration for the virtual investor day can be found by visiting:
<https://info.switzer.com.au/2021-switzer-small-micro-cap-investor-day>

-ENDS-

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome/septic shock.



Veyonda is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has three main drug actions – highly selective inhibition of sphingosine kinase, STING signaling and autophagy. Sphingosine kinase inhibition contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies and immune checkpoint inhibitors; STING signaling inhibition provides an anti-inflammatory effect, contributing to an anti-cancer action, but also potentially blocking sepsis; autophagy inhibition is believed to augment the immunotherapy effect of radiotherapy, in particular the triggering of an abscopal response.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR), and wholly owns Pharmorage, a private drug development company focused on drug development in the areas of sepsis and autoimmunity.

To learn more visit: <https://www.noxopharm.com/>

Investor, Media & Corporate enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the Covid-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



Noxopharm Limited (ASX:NOX)

SWITZER SMALL & MICRO CAP VIRTUAL INVESTOR DAY
March 2021

Dr Graham Kelly
CEO and Managing Director

Discover



Develop



Deliver



Disclaimer



This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.


Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Noxopharm is building a pipeline of drugs based on a unique and proprietary technology platform for the treatment of cancer and septic shock



Of est. 55 million deaths globally from disease:

- ~ **10 million are from cancer***
- ~ **10 million are from septic shock***

- 
- Tissue injury from:
- Viral/bacterial infections
 - Trauma
 - Major surgery
- A blue line with an arrowhead points from the top of this red oval callout box to the "septic shock*" bullet point in the list above.

* World Health Organization (2020)

Link between cancer and septic shock



Both involve abnormal immune and inflammatory responses

Cancer:

- Manipulates the immune system to avoid immune attack
- Increases inflammation to enable growth and spread

Septic shock:


- Acutely excessive inflammation in response to tissue injury



Common underlying mechanism is altering balance between **ceramide** and **sphingosine-1-phosphate**

Veyonda[®] First and only known selective inhibitor of sphingosine kinase 1 to enter the clinic

Veyonda[®] breakthrough COLD to HOT effect



Immune cells driven from tumour

Veyonda restores immune function to tumour

Majority of human tumours are COLD (lacking immune cells)
Converting **COLD** tumours to **HOT** means that standard anti-cancer treatments should work better

Veyonda being developed as a combination drug to boost effectiveness of common cancer treatments

C
A
N
C
E
R

Two clinical studies confirm anti-cancer boost.
3rd key study now underway



C
A
N
C
E
R

DARRT program

- Veyonda + (low-dose) external beam radiotherapy (EBRT)
- Phase I study / 25 men / end-stage prostate cancer
- **Combination delivers major boost to anti-cancer effect of EBRT¹**

LuPIN program

- Veyonda + ¹⁷⁷Lu-PSMA-617 (Novartis)
- Phase I/II study / 56 men / end-stage prostate cancer
- **Combination delivers major boost to reports of anti-cancer effect of Novartis drug alone²**

IONIC program


- Veyonda + Opdivo® (Bristol Myers Squibb)
- Phase I/II study / 30 patients / all forms of solid cancer
- Study started³

1. ASCO ASM June 2020; 2. ASCO Genitourinary Cancer Conference Feb 2021; 3. ASX announcement 19 March 2021

Breakthrough potential treatment of cytokine release syndrome

S
E
P
T
I
C

S
H
O
C
K



NOXCOVID program

- 40 patients with moderate COVID-19 disease
- Requiring hospitalization and low-volume oxygen supplementation
- Dose-escalation arm (400-1800 mg) complete
- Dose-expansion arm (1800 mg) ongoing

Objective: to demonstrate that Veyonda

- Reduces the cytokine release syndrome (CRS)
- Reduces disease progression requiring ICU care and mechanical ventilation
- Reduces incidence of CRS-related disability and death
- Has the potential to be a cost-effective treatment for septic shock generally

SUMMARY



Both DARRT and LuPIN have provided clear evidence of proof-of-concept

IONIC trial

The objective of this trial is to use Veyonda to overcome resistance of most cancers to anti-cancer drug Opdivo® (Bristol Myers Squibb) currently with annual sales of USD8 billion

Veyonda is well tolerated as a combination treatment

Robust IP strategy based on PCT patents around use claims

Our commercial end-point for Veyonda



Noxopharm prepared to take Veyonda all the way to market. However, opportunity as a general booster of most forms of cancer therapy seen as being so large that a partnership potentially is more likely




Currently working with Novartis (USD 200 B) and Bristol Myers Squibb (USD 140 B) drugs in combination therapy



Commercial transaction seen as potentially likely during current Phase 2 trialling

Key metrics

as at 25 March 2021



News Flow (next 6 months)

- IONIC-1 and DARRT-2 start patient recruitment
- COVID-19 clinical trial completion
- Growing first-in-class drug pipeline
- Pharmorage (subsidiary) progressing novel drug development for sepsis and autoimmunity



For further information

email: info@noxopharm.com

web: www.noxopharm.com

twitter: [@noxopharm](https://twitter.com/noxopharm)

Discover



Develop



Deliver

